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Summary Objective: To quantify persistence with inhaled corticosteroids (ICS)
among new users in daily practice and identify determinants of persistence.
Methods: A retrospective cohort study was performed with data from the Dutch
PHARMO system. This system consists of medication and hospital admission records
of 325,000 inhabitants of 12 Dutch cities. In patients who were already using other
drugs with a labeled indication of obstructive lung diseases (ATC: R03), individuals
with a first dispensing of ICS between January 1, 1994 and December 31, 2000 were
identified. Persistence with ICS was defined as the number of days on ICS treatment
in the first year of use. Determinants of persistence were identified one year before
start of the first dispensing of ICS.
Results: Approximately 50% of the patients used inhaled corticosteroids (ICS) for
less than 200 days, while 18% continued treatment for one year. One-year
persistence rates increased to 40% in patients with a history of multiple respiratory
disease related drugs. Persistence rates also increased with lower initial doses, if the
initial prescription was instituted by a medical specialist, if a patient was previously
hospitalized for obstructive lung diseases, and with increasing age.
Conclusion: The persistence rate of ICS is poor. Preventing early treatment
discontinuation may be important to ensure maximal benefit from ICS treatment.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Asthma and COPD are among the leading chronic
disorders in Western society. In Europe alone,
asthma and COPD are ranked as the third most
common cause of death,1 whereas in North America
COPD is listed as the fourth,2 merely exceeded by
heart attacks, cancer, and stroke. Mortality figures
are still on the rise.
In asthma, there is unambiguous clinical evi-
dence that inhaled corticosteroids (ICS) are not
only effective in reducing frequency and severity of
exacerbations, and preventing admission to hospi-
tal and intensive care units, but also improve lung
function, decrease airway hyperresponsiveness,
reduce symptoms, and improve quality-of-life.3,4
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Although treating COPD-patients with ICS seems
to be cost-effective,5 the exact role of these anti-
inflammatory drugs in COPD has yet to be eluci-
dated.6,7
However, COPD is still often recognized as poorly
responsive asthma. In addition, beneficial clinical
effects of ICS were observed in recent randomized
controlled trials, be there: amelioration of
respiratory symptoms, persistent improvement in
airways reactivity, decreased frequency or
severity of exacerbations, diminished use of
healthcare resources, and improved health-related
quality-of-life.8 One observational study suggested
that ICS therapy is associated with reduced
COPD-related morbidity and mortality in elderly
patients.8,9
Lack of persistence of use of ICSFalthough
proven efficacious in clinical studiesFis a threat
for achieving maximum patient benefit, and even
may have serious health consequences.
Persistence studies with other drugs intended for
chronic use (e.g. lipid-lowering drugs, antihyper-
tensives, and estrogen replacement therapy) have
shown very low 1-year persistence ratesFvarying
from 20% to 40%.10–15 As far as we know, no studies
have yet been performed on persistence with ICS in
patients with obstructive lung diseases, and
therefore the rationale of the current study is to
quantify the persistence with ICS therapy among
new users in daily practice, and to identify
determinants of persistence with these anti-inflam-
matory drugs.
Materials and methods
Study subjects
Setting
Data were obtained from 325,000 inhabitants of
twelve cities in the Netherlands who take part in
the PHARMO medical record linkage scheme. The
PHARMO database consists of the complete medi-
cation history for all these patients, linked to their
existing hospital discharge records. The linkage has
a sensitivity and specificity exceeding 95%.16–18 The
computerized drug-dispensing histories contain
data concerning the dispensed drug (identified by
WHO’s Anatomical and Therapeutical Classification
(ATC) system), type of prescriber, dispensing date,
dispensed amount, and prescribed dose regimens.
The hospital records include detailed information
concerning the primary and secondary diagnoses,
procedures, as well as dates of hospital admissions
and discharges. All diagnoses are coded according
to the International Classification of Diseases (ICD)
system, version 9 (ICD-9-CM).
Cohort definition
From the PHARMO database, we extracted all
medical (hospital) and pharmaceutical information
pertaining to the 8-year study period from January
1, 1993 through December 31, 2001. From this data
set we created a cohort consisting of patients of at
least 5 years of age, who had received their first
dispensing of ICS somewhere in the 6-year period
between January 1, 1994 and December 31, 2000.
The types of ICS prescribed included beclometa-
sone, budesonide, or fluticasone. The date of this
first ICS dispensing was considered the index date.
Further, to be included in the cohort, patients
had to be registered in the PHARMO database for at
least 1 year after the index date, and had to be free
from past ICS use. Also, to ensure that ICS was
being prescribed for obstructive lung diseases,
patients who were never dispensed other drugs
with a labeled indication of obstructive lung
diseases (ATC code R03) in the year before or at
the index date were excluded. Patients who did not
refill a prescription of ICS within 1 year were also
excluded from further analysis, as were patients
who started treatment with, or switched to a
combination preparation of an ICS and a long-acting
beta-agonist, because it is hard to assess whether
failure to therapy persistence is attributable to ICS
alone or due to the combination.19,20
Study design
Outcome definition
The persistence on ICS treatment was defined as
the number of days that ICS was used in the period
of 1 year after the index date. One-year persis-
tence rates for ICS were defined as the percentage
of patients that used ICS for at least 365 days.14
Determinants
Determinants of persistence on ICS treatment were
amongst others based on persistence studies done
with other drugs and included age, gender, year of
start of ICS, medical subspecialism of first prescrib-
ing physician, and the initial dose of ICS. All these
potential determinants were ascertained at the
index date.
In the year prior to the index date, proxies for
severity of obstructive lung diseases were assessed
as possible determinants for persistence with ICS
treatment. These markers included hospitalizations
for obstructive lung diseases and prior use of drugs
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with a labeled indication of obstructive lung
diseases, as described by others.21,22
Methods
Persistence with ICS
The prescription patterns were ascertained for
each patient in the first year after the index
dispensing. For each prescription, the legend
duration of use was calculated by dividing the
number of units dispensed by the number of units
to be used per day as defined in the pharmacies. All
prescriptions were subsequently converted into
episodes of consecutive use of ICS. In case of
interruptions between two ensuing prescriptions of
less than 30 days, the episode was considered
uninterrupted. It should be noted that experiments
with smaller and larger permissible lack periods
than 30 days, e.g. 15 and 60 days had only minor
effect on the episode length. Patients who
switched from one type of ICS to another were
considered continuing their ICS therapy. The total
duration of treatment included the permissible
gaps (up to 30 days) between two subsequent
dispensings. Using this definition of persistence,
the ratio of sum of all legend durations of individual
prescriptions/total duration of treatment (includ-
ing gaps) was more than 80% in 95% of the patients.
For patients who remained on treatment at the end
of the study period the duration of treatment was
censored at that date (1 year).
Determinants of persistence
The dose of ICS was expressed as a fraction of
WHO’s defined daily dose (DDD equivalents or
DDDeq). The defined daily doses for the different
ICS were 800 mg for beclomethasone and budeso-
nide and 400 mg for fluticasone. The daily dose for
patients aged 5–16 years was defined as half the
dose for adults. DDDeq were estimated by dividing
the prescribed and defined daily dose. For exam-
ple, the DDDeq of a prescribed daily dose of 1000 mg
beclomethasone with a defined daily dose of 800 mg
is 1000/800¼ 1.25 DDDeq.
Hospitalization for obstructive lung diseases was
defined as a hospitalization with a primary dis-
charge diagnosis of asthma (ICD-9-CM: 493), em-
physema (492), chronic bronchitis (491), and
chronic airway obstruction (496) or a hospitaliza-
tion with a secondary diagnosis (493, 492, 491, 496)
and a primary discharge diagnosis that was related
to obstructive lung diseases such as upper respira-
tory tract infection or pneumothorax.19 The use of
drugs with a labeled indication of obstructive lung
diseases (ATC: R03) included long-acting beta-
agonists (ATC-code: R03AC12 and R03AC13), short-
acting beta-agonists (R03AC, minus R03AC12 and
R03AC13), parasympathicolytics (R03BB), xanthine-
derivatives (R03DA), cromoglycates (R03BC), and
systemic sympathicomimetics (R03C). Other relat-
ing drugs commonly used during treatment of
exacerbations included oral corticosteroids
(H02AB), antibiotics (J01), antihistamines (R06A),
mucolytics (R05CB), cough medications (R05D) and
nasal preparations (R01A).
Analyses
Survival functions describing persistence with ICS
treatment over time were computed using Kaplan
Meier survival analyses. Crude and multivariate
analyses to identify independent determinants of
persistence on ICS treatment were conducted using
Cox’s proportional hazard analyses. Variables sig-
nificantly associated with persistence in the crude
analyses were included in the multivariate analysis.
The same statistical models were used for sub-
group analyses in patients between 15 and 44 years
of ageFrepresenting mainly asthma-patients, and
in patients older than 65 years of ageFrepresent-
ing most likely COPD-patients. Statistical signifi-
cance was defined at an alpha level of 0.05.
Results
A total of 8736 patients met the inclusion criteria of
our study. The characteristics of new users of ICS
are described in Table 1. In 78.4% of the patients
was ICS therapy initially instituted by general
practitioners. Approximately 50% of the patients
filled at least one prescription for another drug
with a labeled indication of obstructive lung
diseases 1 year before the index date; the most
frequently prescribed drugs were the short-acting
beta-agonists (46.6%), while 14.4% and 56.2% had
been dispensed in the 365 days prior to the index
date at least one prescription for short courses of
oral corticosteroids, and/or an antibiotic, respec-
tively. One-hundred and ninety-one patients (2.2%)
had been hospitalized for obstructive lung diseases
at least once in the 1 year period before the index
date.
About one percent of the new ICS users had only
been using anti-tussive agents in the period before
the index date, implying low disease severity, while
another 1.0% had been using several drugs with a
labeled indication of obstructive lung disease in
conjunction with oral corticosteroids and antibio-
tics, suggesting moderate to high disease severity.
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Table 1 Characteristics of new users of inhaled corticosteroids 1994–2000 (N ¼ 8; 736).
Characteristics Number %
At start of ICS
Gender Male 3994 45.7
Female 4742 54.3
Age group (year) 5–14 1376 15.8
15–44 3005 34.4
45–64 2306 26.4
X65 2049 23.5
Year of start 1994 1823 20.9
1995–1996 2759 31.6
1997–1998 2488 28.5
1999–2000 1666 19.1
Type of ICS Beclomethasone 4105 47.0
Budesonide 2712 31.0
Fluticasone 1919 22.0
Inhaler type Metered dose 1484 17.0
Dry-powder 7252 83.0
Daily dose at start (DDDeq) 0–0.74 2996 34.0
0.75–1.24 3339 38.2
X1.25 2431 27.8
Prescriber General practitioner 6853 78.4
Specialist 1883 21.6
One year prior to start of ICS
Use of respiratory disease related drugs
I. asthma/COPD drugs Long-acting beta-agonists 237 2.7
Short-acting beta-agonists 4069 46.6
Cromones/Nedocromil 425 4.9
Parasympathicolytics 1096 12.5
Sympathicomimetics 403 4.6
Xanthine-derivatives 185 2.1
Number of asthma/COPD drugs 1 4477 51.2
X2 891 10.2
II. Other drugs Antihistamines 1781 20.4
Coughing agents 1296 14.8
Mucolytics 1406 16.1
Nasal preparations 1552 17.8
Number of other drugs 1 2911 33.3
X2 1421 16.3
Use of oral corticosteroids Yes 1260 14.4
Use of antibiotics Yes 4906 56.2
Hospitalisation Yes 191 2.2
Markers of disease severityn
Anti-cough medication only, no asthma/COPD drugs, no oral
corticosteroids
97 1.1
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The majority (43.6%) of the patients had low to
moderate disease severity, as illustrated by the use
of merely one type of asthma/COPD drug before
the index date.
From the total cohort, 1539 patients (17.6%)
continued ICS treatment for one year, whereas 50%
of the patients used ICS for less than 196 days
(95%CI: 192–200) during their first year of follow-
up. The 1-year persistence rate with ICS-therapy
differed for patients with different medication
(Fig. 1 and Table 2). One-year persistence with
ICS was low (10%) in patients who had been using
merely anti-cough medication, indicating low dis-
ease severity or off-label prescribing, and this rate
increased to 40% in patients with a moderate
disease severity, as indicated by utilization of
multiple different respiratory disease related
drugs, including a combination of oral corticoster-
oids and antibiotics. Other determinants of
statistically significant higher persistence rates
with ICS were, in relative order of highest relative
risk, low starting dose of ICS, specialist as the
first prescribing physician, one or more hospital-
izations in the 1-year period prior to the index
date, and older age. Persistence rates were
decreased for patients that started ICS therapy
in the period of 1999–2000 compared to 1994
(Table 2).
Discussion
The present study indicates that overall, one out of
two patients starting on ICS therapy discontinues
treatment within 6 months, and that only one out
of 5 persists with ICS treatment for one year.
Persistence with ICS use is clearly related to
severity of obstructive lung disease, as illustrated
by the increase of this rate to about 40% in patients
using multiple different respiratory disease related
medicationsFalbeit it still very poor. That severity
plays a role in persistence, is also shown by the
finding that the persistence rate in patients who
had been hospitalized at least once for an
obstructive lung disease was higher compared to
patients who had not been admitted in the year
before the index date.
Lack of persistence of use of ICSFdrugs that
have been unambiguously shown to be efficacious
in clinical trials in asthma patients in reducing
frequency and severity of exacerbations, in pre-
venting admission to hospital and intensive care
units, in improving lung function, decreasing airway
hyperresponsiveness, and in improving quality-of-
life of asthma patients3,4Fis a threat to achieving
maximum patient benefit. Studies have demon-
strated that discontinuation of ICS as part of
intervention studies, results into deterioration of
the clinical condition, an increased need for
additional (inhaled) corticosteroids, as well as a
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Table 1 (continued)
Characteristics Number %
One asthma/COPD drug, no oral corticosteroids 3811 43.6
More than one asthma/COPD drug, no oral corticosteroids 615 7.0
More than one asthma/COPD drug and a combination of oral
corticosteroids and antibiotics
88 1.0
Undefinedw 4125 47.2
nGroups are mutual exclusive.
wFor example patients that received other drugs like antihistamines, and mucolytics, or combinations of different types of
drugs.
Persistence with inhaled corticosteroids (days)
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Figure 1 Persistence on ICS treatment in the first year
after the index date. Persistence was defined as the total
number of days that ICS were used. (1. Undefined, 2.
Anti-cough medication only, no respiratory disease
related drugs (ATC code¼R03), no oral corticosteroids,
3. One respiratory disease related drug, no oral corticos-
teroids, 4. Multiple respiratory disease related drugs, no
oral corticosteroids, 5. Multiple respiratory disease
related drugs and combination of oral corticosteroids
and antibiotics).
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statistically faster annual FEV1 decline compared to
control subjects.23
Although treating COPD-patients with ICS seems
to be cost-effective,5 the exact role of these anti-
inflammatory drugs in COPD is less clear.6,7 How-
ever, COPD is still often recognized as poorly
responsive asthma. In addition, a study by Jack-
evicius et al.24 has shown that ICS was more
commonly prescribed for COPD (43%) than for
asthma (37%) and that there was little difference
in the use of ICS for asthma and COPD patients.25
Aforementioned is in contradiction with COPD
management guidelines. These recommend a trial
period of ICS, and advise to discontinue ICS therapy
if no objective or perceived clinical improvement
can be discerned. Thus, including COPD-patients in
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Table 2 One-year persistence rates in patients with relevant determinants of persistence with ICS treatment.
Characteristics of patients Number Patients persistent
for one year (%)n
RRadj
w (95% CI)
All patients 8736 17.6
Subgroups of patients
Age (years)
5–14 1376 14.5 0.87 (0.80–0.95)
15–44 3005 11.9 1.0 (ref)
45–64 2306 20.3 1.33 (1.25–1.41)
464 2049 25.2 1.57 (1.47–1.68)
Year of start
1994 1823 18.3 1.0 (ref)
1995–1996 2759 17.8 0.96 (0.90–1.02)
1997–1998 2488 18.9 1.02 (0.95–1.09)
1999–2000 1666 14.6 0.86 (0.80–0.92)
Prescriber
General practitioner 6853 15.0 1.0 (ref)
Specialist 1883 27.2 1.61 (1.52–1.72)
Dose at start (DDDeq)
0–0.74 2996 18.7 1.64 (1.52–1.78)
0.75–1.24 4111 17.6 1.24 (1.13–1.28)
X1.25 1629 16.3 1.0 (ref)
Hospitalisation in year prior to index
date
No 8545 17.2 1.0 (ref)
Yes 191 37.7 1.54 (1.28–1.86)
Previous medication use as a proxy
for asthma severity
Anti-cough medication only, no
asthma/COPD drugs, no oral
corticosteroids
97 10.3 1.0 (ref)
One asthma/COPD drug, no oral
corticosteroids
3811 16.1 1.24 (1.00–1.53)
More than one asthma/COPD drug,
no oral corticosteroids
615 27.3 1.70 (1.35–2.15)
More than one asthma/COPD drug,
and a combination of oral
corticosteroids and antibiotics
88 37.5 2.16 (1.54–3.03)
Undefined 4125 17.9 1.17 (0.94–1.44)
nCrude persistence rates, not adjusted for other factors.
wAll variables were analysed in the same model. RR41 means that the variable increases persistence with ICS therapy.
Persistence with inhaled corticosteroid therapy 757
the current study might underestimate the actual
persistence rate of ICS therapy. Regrettably, we
lacked data on diagnoses, and were therefore not
able to objectively distinguish between asthma and
COPD. However, stratified analysis in patients
between 15 and 44 years of age (predominantly
asthma-patients), and patient of 65 year and older
(majority likely to be COPD-patients), yielded no
substantial difference in persistence rate, nor in
determinants of persistence (data not shown). In
fact, as discussed above, persistence rates were
higher in older aged patients.
In order to include patients that used ICS for
chronic diseases only, we excluded patients that
did not refill their ICS prescription within one year.
Our data still contained a considerable number of
patients (50%) that had not used respiratory drugs
before the start of ICS. This is a remarkable finding
for asthma/COPD patients, but consistent with
recently published data on the use of ICS in the
United Kingdom.26 On the other hand, 81% of the
patients used short-acting b-agonists or parasym-
pathicolytics during follow-up (results not shown).
Another factor that might have underestimated
the actual persistence rate is that we excluded
combination compounds of inhaled corticosteroids
and long-acting beta-agonists. However, we hy-
pothesized that patients on these combinations
products would be more persistent because of the
direct noticeable bronchodilating effect of
long-acting beta-agonists, and not because of the
effect of ICS, which are not directly apparent.
During the study period only 1.3% of the patients in
the source population started on the fixed combi-
nation and only 1.9% of the patients starting with
ICS had a dispensing for a fixed combination
preparation in the follow-up period of 1 year.
Hence, the actual persistence rate would not be
much influenced by excluding patients on these
combinations and exclusion of these patients can
not explain the low persistence rates of ICS
observed in this study.
The low persistence rates observed in the current
study are corroborated by studies that have shown
low compliance rates for ICS (30–60%).27–30 These
and other compliance studies revealed that many
patients do not understand the role of their
medications, have problems with the inhalation
devices or have misconceptions and fears with
regard to ICS, reducing their willingness to use
them.29,31,32
Low persistence rates (20–40%) have also been
described for many other drugs intended for long-
term use, like lipid-lowering drugs, anti-hyperten-
sives, estrogen replacement therapy, osteoarthro-
sis and antidiabetics.13,14 These studies and the
current studyFas discussed aboveFhave shown a
relationship between persistence and severity of
the disease intended to treat, suggesting that more
severe patients are more likely to take medications
as directed because of the perceived need to treat
their condition effectively11,14,29.
Persistence was also been found to be lower in
patients who started on higher daily doses of ICS,
implying that persistence might be facilitated by
prescription of the lowest possible doses. An
explanation for the latter could be that patients
experienced side effect on higher doses.33 Although
systemic side effects are seen less often by the
inhaled than the oral route, there is growing
awareness of unwanted systemic effects of inhaled
steroid use given the availability of high-concen-
tration formulations.34
Also, in patients in whom ICS therapy was initially
instituted by a specialist showed higher persistence
ratesFsomething that is also observed in other
studies on persistence.12,13 This could be due to a
difference in disease severity between patients
treated by a medical specialist as compared to
patients treated by generalists. Alternatively, as
has been suggested in persistence studies for other
pharmacotherapeutic areas, it might be indicative
of greater persuasiveness of specialists, being more
aware of the need for continued supervision and
support.30 Although there are no studies in patients
with obstructive lung diseases, as far as we know,
that supports the latter in our patients.
In analogy to others,21,22 short courses of
corticosteroids and antibiotics, as well as the use
of different types of drugs with a labeled indication
of obstructive lung diseases were used as markers
of disease severity. This is also in agreement with
an add-on-step-down approach as recommended in
different obstructive lung disease management
guidelines. We do realize that not every physician
will diminish the number of different drugs once a
patient’s disease is under control. For sure, a
better marker for severity would be clinical
measurement. However, we had no data on lung
function tests to our disposal.
In conclusion, the current study has shown that
new users of ICS had worrying low persistence with
ICS-therapy in the first year of follow-up. Prevent-
ing this early treatment discontinuation is of crucial
importance to ensure maximal benefit from ICS
treatment.
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